Keyword: Entresto

Zolgensma hauled in $160 million in its first full quarter on the market, more than 60% above the Street's expectations.

AstraZeneca's Farxiga has new CV data that could help the entire SGLT2 class—and even pressure heart medicines outside the class, too. 

With a trial setback for its $5 billion CV hopeful in its way, Novartis is looking at the bright side—Entresto flopped, but it was a “narrow miss.”

Novartis envisioned $5 billion in peak sales for its cardiovascular drug Entresto, but, after a major trial flop, that goal appears out of reach.

Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”

A handful of branded drug ads are using popular ‘70s light rock songs, both to aid recall and to reach older audiences with music from their youth.

Cosentyx and Entresto delivered strong growth again, but Novartis CEO Vas Narasimhan took pains to explain a death case in a Zolgensma trial.

It's been a long slog through a sluggish launch, but Novartis' highly anticipated heart drug Entresto has finally reached blockbuster status.

Novartis is raising its 2018 sales outlook, but canakinumab won’t help it hit the new target—at least not in the cardiovascular sales department.